Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + arsenic trioxide + gemtuzumab ozogamicin for relapsed acute promyelocytic leukemia
jRCTs041190101Active, not recruiting
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamibarotene, arsenic trioxide and gemtuzumab ozogamicin in Acute promyelocytic leukaemia (APL). Primary endpoint: 1-year event-free survival rate. Started Feb 2020; status: active, not recruiting.
02
Drugs
tamibarotenearsenic trioxidegemtuzumab ozogamicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs041190101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190101.